Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
Titel:
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
Auteur:
Haqq, Andrea M Chung, Wendy K Dollfus, Hélène Haws, Robert M Martos-Moreno, Gabriel Á Poitou, Christine Yanovski, Jack A Mittleman, Robert S Yuan, Guojun Forsythe, Elizabeth Clément, Karine Argente, Jesús